Oncology clinical trial disruption during the COVID-19 pandemic: a COVID-19 and cancer outcomes study
Ziad Bakouny(Dana-Farber Cancer Institute), Deborah B. Doroshow(Icahn School of Medicine at Mount Sinai), Matthew D. Galsky(Icahn School of Medicine at Mount Sinai), Catherine Curran(Dana-Farber Cancer Institute), Alaina J. Kessler(Icahn School of Medicine at Mount Sinai), Michelle Evans(Mount Sinai Hospital), Gabrielle Bouchard(Dana-Farber Cancer Institute), Talal El Zarif(Yale University), Brittney S. Zimmerman(Icahn School of Medicine at Mount Sinai), Jennifer Cocco(Icahn School of Medicine at Mount Sinai), Sheena Bhalla(Icahn School of Medicine at Mount Sinai), C. Labaki(Dana-Farber Cancer Institute), Fiona Busser(Dana-Farber Cancer Institute), John A. Steinharter(Memorial Sloan Kettering Cancer Center), Laure Hirsch(Harvard University), Toni K. Choueiri(Harvard University), Bruce E. Johnson(Harvard University), Pier Vitale Nuzzo(Dana-Farber Cancer Institute), Tomi Jun(Sema4 (United States)), Kaitlin M. Kelleher(Dana-Farber Cancer Institute), Hsin-Hui Huang(Icahn School of Medicine at Mount Sinai), Jonathan Feld(Icahn School of Medicine at Mount Sinai), Sara M. Tolaney(Harvard University), Michael Wotman(The University of Texas MD Anderson Cancer Center), Penina S. Stewart(Icahn School of Medicine at Mount Sinai), Quoc‐Dien Trinh(University of Pittsburgh Medical Center), Robert I. Haddad(Georgetown University), Douglas Tremblay(Icahn School of Medicine at Mount Sinai), Catherine M. Champagne(Pennington Biomedical Research Center), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Danielle Seidman(Icahn School of Medicine at Mount Sinai), Andrew Schmidt(Dana-Farber Cancer Institute), Talia D. Rosenbloom(Icahn School of Medicine at Mount Sinai), Sarah Abou Alaiwi(Yale New Haven Hospital), Heather Anderson-Keightly(Icahn School of Medicine at Mount Sinai), Qian Qin(Icahn School of Medicine at Mount Sinai)
Cited by 33
Related Papers
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
|Science|2004|9.4k
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k